Navipharm is rushing on patent challenges while Handok Teva had its debut
Competition to acquire the Priority Sale Item Approval Rights has been activated among generic pharmaceutical companies. The IP R&D company, Navipharm, has made sudden movements, facing the ‘Patent Linkage System’.
Moreover, Handok Teva, co-invested by the global generic company, Teva, and Hando...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
